On Feb. 7, the FDA resumed its routine, domestic clinical trial inspections under the Bioresearch Monitoring Program (BIMO).

The agency’s decision to resume routine, domestic surveillance applies to all of its program areas, an FDA spokesperson confirmed to CenterWatch Weekly. They noted that the agency’s mission-critical inspections have continued to be conducted throughout the temporary pause.

The agency said it will continue to use a variety of tools to conduct both domestic and overseas mission critical inspections, including remote assessments.